Today, I want to show you how all these warning signs are converging… and how they’re about to reach a breaking point. I’ll expose what is really going on behind the scenes in D.C…

Watch my broadcast now: How to survive the coming crisis

Junge Zhang Biography and Net Worth

Director of Ocugen

Dr. Junge (John) Zhang is the Founder, President, and CEO of Biopeptek, a company that specializes in the research and development of peptides. Since its founding in 2010, Dr. Zhang has established a company with over 50 experienced scientists and a state-of-the-art facility that is capable of producing high quality custom peptides for research and therapeutic uses. Through his many collaborations with major pharmaceutical companies and research institutions, Dr. Zhang is passionate about research to improve human health.

Prior to founding Biopeptek, Dr. Zhang was with the Janssen Pharmaceutical division of Johnson & Johnson. During his 9-year tenure at J&J, Dr. Zhang held numerous scientific and management positions and led multiple development projects related to three antibody drugs that received FDA approval. Prior to J&J, Dr. Zhang was a Senior Chemist at Eisai USA.

Dr. Zhang earned a Ph.D. in analytical chemistry from Drexel University, a M.S. in chemistry from University of Louisiana, and a B.S. in material science from Wuhan University of Technology in China. Dr. Zhang was born and raised in Qingdao China and immigrated to the United States to pursue his graduate education.

What is Junge Zhang's net worth?: The estimated net worth of Junge Zhang is at least $1.05 million as of June 14th, 2023. Mr. Zhang owns 1,077,182 shares of Ocugen stock worth more than $1,045,621 as of November 8th. This net worth approximation does not reflect any other investments that Mr. Zhang may own. Learn More about Junge Zhang's net worth.
How do I contact Junge Zhang?: The corporate mailing address for Mr. Zhang and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Junge Zhang's contact information.
Has Junge Zhang been buying or selling shares of Ocugen?: Junge Zhang has not been actively trading shares of Ocugen within the last three months. Most recently, on Wednesday, June 14th, Junge Zhang bought 200,278 shares of Ocugen stock. The stock was acquired at an average cost of $0.50 per share, with a total value of $100,139.00. Following the completion of the transaction, the director now directly owns 1,077,182 shares of the company's stock, valued at $538,591. Learn More on Junge Zhang's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Junge Zhang Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2023	Buy	200,278	$0.50	$100,139.00	1,077,182
11/3/2021	Sell	150,300	$17.32	$2,603,196.00
12/4/2019	Buy	220,000	$0.40	$88,000.00
11/27/2019	Buy	270,000	$0.37	$99,900.00	600,078
11/25/2019	Buy	115,000	$0.27	$31,050.00	215,078
11/22/2019	Buy	80,000	$0.28	$22,400.00	215,078
11/18/2019	Buy	100,000	$0.41	$41,000.00	135,078
10/11/2019	Buy	4,000	$1.82	$7,280.00
9/30/2019	Buy	31,078	$3.09	$96,031.02

Junge Zhang Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.97

$0.95

$1.13

50 Day Range

MA: $1.04

$0.89

$1.30

2 Week Range

Now: $0.97

$0.35

$2.11

Volume

7,154,463 shs

Average Volume

6,149,071 shs

Market Capitalization

$279.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.75

Urgent: This election is rigged

From Porter & Company | Ad